Ecallantide

證據等級: L5

預測適應症: 6 個

Ecallantide: From Hereditary Angioedema to C1 Inhibitor Deficiency — A Confirmatory, Not Novel, Signal

One-Sentence Summary

Ecallantide (DrugBank DB05311) is a recombinant plasma kallikrein inhibitor historically known as Kalbitor, publicly documented as having been developed for acute attacks of Hereditary Angioedema (HAE) — though this evidence pack’s own original_indications field is empty and cannot confirm that. The TxGNN model’s top prediction is C1 inhibitor deficiency, which is the underlying pathophysiology of HAE itself, supported by 7 clinical trials (including 2 completed Phase 3 RCTs) and 20 publications. This is best read as the model rediscovering an existing, well-evidenced use rather than surfacing a genuinely new indication — and the drug currently shows zero active market licenses.

Quick Overview

Item	Content
Original Indication	Not recorded in evidence pack (`original_indications` is empty). Publicly known historical use: acute attacks of Hereditary Angioedema (marketed as Kalbitor)
Predicted New Indication	C1 inhibitor deficiency
TxGNN Prediction Score	99.99%
Evidence Level	L1
US Market Status	✗ Not marketed
Number of NDAs	0
Recommended Decision	Proceed with Guardrails

Note: C1 inhibitor deficiency is the causal defect behind Hereditary Angioedema — the same disease ecallantide is already publicly known to treat. This prediction should not be treated as a novel repurposing candidate until the discrepancy in the evidence pack’s original-indication field is resolved.

Why is This Prediction Reasonable?

Detailed mechanism-of-action data is not available in this evidence pack (flagged as DG002, High severity). Based on established public information, ecallantide is a recombinant protein and potent, selective inhibitor of plasma kallikrein — the enzyme responsible for generating bradykinin via the kallikrein-kinin pathway.

C1 inhibitor deficiency (hereditary or acquired) removes the normal brake on plasma kallikrein activity, leading to excess bradykinin generation, increased vascular permeability, and the recurrent angioedema attacks characteristic of HAE. Ecallantide’s kallikrein-inhibiting action addresses this pathophysiology directly, which is consistent with both the very high TxGNN score (99.99%) and the depth of completed Phase 3 evidence below.

Because this mechanistic link is direct rather than inferred through indirect network proximity, and because ecallantide is publicly documented as already used for this exact disease process, the “prediction” here functions more as a validation check on the TxGNN model than as a discovery of new therapeutic potential. The evidence pack’s missing original_indications field should be filled in to confirm this before the candidate is scored as a true repurposing opportunity.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00457015	Phase 3	Completed	96	EDEMA4: randomized, double-blind, placebo-controlled trial of ecallantide (DX-88) for acute HAE attacks
NCT00262080	Phase 3	Completed	91	Double-blind, placebo-controlled study followed by repeat-dosing phase for acute HAE attacks
NCT00456508	Phase 3	Completed	147	Open-label continuation of DX-88 for repeated HAE attacks; follow-up cohort of EDEMA4 patients
NCT01826916	Phase 2	Completed	77	EDEMA2: open-label dose-ranging study of repeated dosing in HAE patients
NCT01059526	N/A (Phase 4)	Completed	81	Long-term observational safety study evaluating immunogenicity and hypersensitivity with KALBITOR exposure
NCT01832896	Phase 2	Withdrawn	0	Planned tolerability/safety study of single SC dose in children and adolescents with HAE
NCT01253382	Phase 2/3	Withdrawn	0	Planned PK, safety, and efficacy study in prepubertal pediatric patients with acute HAE attacks

Literature Evidence

PMID	Year	Type	Journal	Key Findings
21760740	2011	Review	Clin Cosmet Investig Dermatol	Ecallantide as a novel treatment for HAE attacks due to C1 inhibitor deficiency
23406939	2013	Case series	Allergy Asthma Proc	Ecallantide for acute attacks of acquired C1 esterase inhibitor deficiency
22472866	2012	Review	Am J Health Syst Pharm	Pharmacology, efficacy, safety, and place in therapy of ecallantide for HAE
33602658	2021	Review	J Investig Allergol Clin Immunol	Overview of current and emerging therapies for C1-INH-HAE
27503784	2017	Consensus	Allergy	International consensus on diagnosis and management of pediatric C1-INH-HAE
26512744	2016	Review	Expert Opin Pharmacother	Current treatment options for HAE due to C1 inhibitor deficiency
29357215	2018	Review	Skin Therapy Lett	New treatments for HAE, including kallikrein-kinin pathway–targeted drugs
28687105	2017	Review	Immunol Allergy Clin North Am	Acquired C1 inhibitor deficiency: diagnosis and disease associations
28687108	2017	Review	Immunol Allergy Clin North Am	Acute management strategies for HAE attacks
26429506	2015	Review	Expert Opin Drug Saf	Safety profile of treatments for angioedema with hereditary C1 inhibitor deficiency

US Market Information

Currently no marketing authorization records in the evidence pack (total_licenses: 0, market status: not marketed).

Safety Considerations

Please refer to the package insert for safety information. TFDA/FDA label data (warnings, contraindications) is a Blocking data gap (DG001) — this must be resolved before the candidate can proceed to safety pre-assessment (S1).

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale:

Efficacy evidence is strong (L1: two completed Phase 3 RCTs plus a broad literature base), but the missing original_indications data means this may be a rediscovery of an already-known use rather than a new repurposing opportunity, and the drug currently has zero active market licenses.
The Blocking safety data gap (TFDA label) prevents completion of the S1 safety pre-assessment regardless of efficacy strength.

To proceed, the following is needed:

Resolve DG001: obtain TFDA/FDA package insert (warnings, contraindications) to unblock S1 safety review
Resolve DG002: confirm mechanism of action via DrugBank API
Clarify why original_indications is empty — confirm whether ecallantide’s historical approved indication is in fact the same as this “predicted” indication
Confirm current market/registration status given 0 active licenses (e.g., discontinued product vs. never registered)
Drug-drug interaction data (DDI query returned no results)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.